Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
ENZY's Cash-to-Debt is ranked higher than
76% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. ENZY: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ENZY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.46  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.93
ENZY's Equity-to-Asset is ranked higher than
90% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ENZY: 0.93 )
Ranked among companies with meaningful Equity-to-Asset only.
ENZY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.67  Med: 0.92 Max: 0.93
Current: 0.93
0.67
0.93
Interest Coverage No Debt
ENZY's Interest Coverage is ranked lower than
99.99% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ENZY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ENZY' s Interest Coverage Range Over the Past 10 Years
Min: 8.09  Med: 30.19 Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 11.23
Beneish M-Score: -2.79
WACC vs ROIC
7.21%
-5.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -10.17
ENZY's Operating Margin % is ranked higher than
68% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. ENZY: -10.17 )
Ranked among companies with meaningful Operating Margin % only.
ENZY' s Operating Margin % Range Over the Past 10 Years
Min: -10.17  Med: 13.15 Max: 18.1
Current: -10.17
-10.17
18.1
Net Margin % -9.50
ENZY's Net Margin % is ranked higher than
68% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. ENZY: -9.50 )
Ranked among companies with meaningful Net Margin % only.
ENZY' s Net Margin % Range Over the Past 10 Years
Min: -9.5  Med: 12.95 Max: 17.54
Current: -9.5
-9.5
17.54
ROE % -3.14
ENZY's ROE % is ranked higher than
73% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. ENZY: -3.14 )
Ranked among companies with meaningful ROE % only.
ENZY' s ROE % Range Over the Past 10 Years
Min: -3.14  Med: 4.12 Max: 6.52
Current: -3.14
-3.14
6.52
ROA % -2.89
ENZY's ROA % is ranked higher than
75% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. ENZY: -2.89 )
Ranked among companies with meaningful ROA % only.
ENZY' s ROA % Range Over the Past 10 Years
Min: -2.89  Med: 5.18 Max: 12.16
Current: -2.89
-2.89
12.16
ROC (Joel Greenblatt) % -6.79
ENZY's ROC (Joel Greenblatt) % is ranked higher than
75% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. ENZY: -6.79 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ENZY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6.79  Med: 12.6 Max: 28.12
Current: -6.79
-6.79
28.12
3-Year Revenue Growth Rate -33.10
ENZY's 3-Year Revenue Growth Rate is ranked lower than
79% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. ENZY: -33.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ENZY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -33.1 Max: -5
Current: -33.1
3-Year EBITDA Growth Rate -88.80
ENZY's 3-Year EBITDA Growth Rate is ranked lower than
99% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. ENZY: -88.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ENZY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -88.8 Max: -4.4
Current: -88.8
GuruFocus has detected 1 Warning Sign with Enzymotec Ltd $ENZY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ENZY's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ENZY Guru Trades in Q2 2016

Jim Simons 241,000 sh (+33.15%)
John Paulson 4,224,139 sh (unchged)
Julian Robertson 577,407 sh (-49.49%)
» More
Q3 2016

ENZY Guru Trades in Q3 2016

Julian Robertson 677,548 sh (+17.34%)
Jim Simons 258,300 sh (+7.18%)
John Paulson 4,205,980 sh (-0.43%)
» More
Q4 2016

ENZY Guru Trades in Q4 2016

Jim Simons 290,000 sh (+12.27%)
Julian Robertson 677,548 sh (unchged)
John Paulson 4,205,980 sh (unchged)
» More
Q1 2017

ENZY Guru Trades in Q1 2017

John Paulson 4,205,980 sh (unchged)
Julian Robertson 677,548 sh (unchged)
Jim Simons 288,700 sh (-0.45%)
» More
» Details

Insider Trades

Latest Guru Trades with ENZY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325411    SIC: 2833
Compare:NAS:NYMX, NAS:MNOV, OTCPK:SPRWF, NAS:IMDZ, NAS:KURA, NAS:MDGL, OTCPK:SPHRY, NAS:CEMP, OTCPK:OXBDF, OTCPK:BCDA, NAS:CORI, OTCPK:PRMCF, NAS:NVLN, NAS:TRVN, NAS:CLSD, NAS:VRNA, NAS:PTGX, OTCPK:ELVAF, AMEX:OCX, NAS:PIRS » details
Traded in other countries:EZ4.Germany,
Headquarter Location:Israel
Enzymotec Ltd is a nutritional ingredients and medical foods company. The Company develops, manufactures, markets and sells bio-functional lipid ingredients, as well as final products, based on sophisticated proprietary processes and technologies.

Top Ranked Articles about Enzymotec Ltd

Enzymotec to Report First Quarter 2017 Financial Results
VAYA Pharma Introduces New Three-Month Supply of Vayarin® and Vayacog® Medical Foods
Neptune and Enzymotec Reach Patent Agreement Ending All Litigation
Enzymotec Files Annual Report on Form 20-F for the Year Ended December 31, 2016

MIGDAL HA'EMEQ, Israel, March 16, 2017 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (NASDAQ:ENZY) ("Enzymotec" or the "Company"), a developer, manufacturer and marketer of innovative bio-active lipid-based nutritional ingredients and medical foods, today announced that that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2016 with the U.S. Securities and Exchange Commission (“SEC”). The annual report on Form 20-F, which contains audited financial statements, can be accessed on the SEC’s website at http://www.sec.gov as well as via the Company’s investor relations website at http://ir.enzymotec.com.
The Company will also deliver a hard copy of its annual report on Form 20-F, including its complete audited financial statements, free of charge, to its shareholders upon request to Oren Bryan at [email protected]. About Enzymotec Ltd. Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies. For more information, visit www.enzymotec.com.
Company Contact

Enzymotec Ltd.
Oren Bryan
Chief Financial Officer
Phone: 972747177177
[email protected]

Contact

The Ruth Group
Tram Bui / Lee Roth
Phone: 646-536-7035 / 7012
[email protected]
[email protected]

Read more...
Enzymotec Ltd. Calls an Extraordinary General Meeting of Shareholders

MIGDAL HA’EMEQ, Israel, March 10, 2017 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (NASDAQ:ENZY) (the “Company”), today announced that it will hold an Extraordinary General Meeting of Shareholders (the “Meeting”) at 10:00 am local time on Tuesday, April 25, 2017 at the Company’s offices, at Sagi 2000 Industrial Area, Migdal Ha’Emeq 2310001, Israel. The record date for shareholders entitled to vote at the Meeting is Thursday, March 16, 2017.
The Meeting is being called for the following purpose: To approve the compensation of Mr. Erez Israeli, the Company’s newly appointed President and Chief Executive Officer and, in connection therewith, approve a one-time increase in the number of ordinary shares available for grant under the Company’s 2013 Omnibus Equity Incentive Plan. The Board of Directors unanimously recommends that shareholders vote FOR the above proposal, which will be described in a proxy statement to be made available to the Company’s shareholders. The shareholders may also act upon such other matters as may properly come before the Meeting or any adjournment or postponement thereof. Approval of the above proposal requires the affirmative vote of the holders of a majority of the voting power represented at the Meeting in person or by proxy and voting on the proposal. In addition to the foregoing simple majority requirement, under the Israeli Companies Law 5759-1999 (the “Israeli Companies Law”), the approval of the compensation of the Company’s new President and Chief Executive Officer under the proposal also requires that either: the majority voted in favor of the proposal includes a majority of the ordinary shares held by non-controlling shareholders who do not have a conflict of interest (referred to as a “personal interest” under the Israeli Companies Law) in the approval of the proposal that are voted at the meeting, excluding abstentions; or
the total number of ordinary shares held by non-controlling, non-conflicted shareholders (as described in the previous bullet-point) voted against approval of the proposal does not exceed two percent (2%) of the aggregate voting rights in the Company. The presence (in person or by proxy) of any two or more shareholders holding, in the aggregate, at least 25% of the voting rights in the Company constitutes a quorum for purposes of the Meeting. In the absence of the requisite quorum of shareholders at the Meeting, the Meeting will be adjourned to the same day in the next week, at the same time and place, unless otherwise determined at the Meeting in accordance with the Company’s articles of association. At such adjourned meeting the presence of at least two shareholders in person or by proxy (regardless of the voting power represented by their shares) will constitute a quorum. Shareholders who are unable to attend the Meeting in person will be requested to complete, date and sign their proxy cards and return them promptly in the pre-addressed envelope that will be provided, so as to be received not less than forty eight (48) hours in advance of the Meeting, unless such deadline is waived by the chairman of the Meeting. No postage will be required if it is mailed in the United States to the Company’s United States transfer agent, American Stock Transfer & Trust Company. Shareholders who attend the Meeting in person may revoke their proxies and vote their ordinary shares at the Meeting. If your ordinary shares in the Company are held in “street name” (meaning held through a bank, broker or other nominee), you will be able to either direct the record holder of your shares on how to vote your shares or obtain a legal proxy from the record holder to enable you to participate in and to vote your shares at the Meeting (or to appoint a proxy to do so). Additional Information and Where to Find It In connection with the Meeting, the Company will make available to its shareholders of record a proxy statement describing the time and place, and other logistical information related to the Meeting, and the proposal to be voted upon at the Meeting, along with a proxy card enabling them to indicate their vote on the proposal. The Company will also furnish copies of the proxy statement and proxy card to the Securities and Exchange Commission, or SEC, on a Report of Foreign Private Issuer on Form 6-K, which may be obtained for free from the SEC’s website at www.sec.gov and will be available on the Company’s  website at www.enzymotec.com. The full text of the proposed resolution for the Meeting, together with the form of proxy card, may also be viewed beginning on Monday, March 20, 2017, at the registered office of the Company, Sagi 2000 Industrial Area, Migdal Ha’Emeq 2310001, Israel, from Sunday to Thursday (excluding holidays), 10:00 a.m. to 5:00 p.m. (Israel time).  The Company’s telephone number at its registered office is 972-74-717-7177. About Enzymotec Ltd. Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies.  For more information, visit www.enzymotec.com.
Company Contact
Enzymotec Ltd.
Oren Bryan
Chief Financial Officer
Phone: 972747177177
[email protected]

Investor Relations Contact (U.S.)
The Ruth Group
Tram Bui / Lee Roth
Phone: 646-536-7035 / 7012
[email protected]
[email protected]

Read more...
Enzymotec Ltd. Announces the Appointment of Erez Israeli as President and CEO

MIGDAL HA'EMEQ, Israel, March 09, 2017 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (NASDAQ:ENZY) ("Enzymotec" or the "Company"), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, today announced that its Board of Directors has appointed Erez Israeli as President and Chief Executive Officer effective April 18, 2017. Mr. Israeli succeeds Dr. Ariel Katz, who has served as Enzymotec’s President and Chief Executive Officer since 2001.
“I am excited and pleased to welcome Erez to the Enzymotec team as President and Chief Executive Officer. We believe that Erez’s years of experience, strategic vison and leadership capabilities will support a seamless leadership transition,” commented Steve Dubin, Enzymotec’s Chairman of the Board. “Erez has developed transformational strategies at Teva Pharmaceuticals to generate commercial growth in complex multi-national organizations and has helped drive the efficiency and effectiveness of sales and marketing teams. Those capabilities will serve Erez and Enzymotec well as we seek to strategically grow our core businesses and position the Company for long-term success. I would also like to thank Dr. Ariel Katz for his many years of leadership and innovative vision at Enzymotec. His work has helped lay the foundation for a robust business from which we can build.” Mr. Israeli has more than 20 years of experience in strategic planning, business processes, operation, quality, finance and global sales and marketing. Mr. Israeli was most recently the President and CEO of Growth Markets at Teva Pharmaceuticals where he oversaw all commercial activities in Asia, Asia Pacific, Africa and Latin America. Since joining Teva in 1994, he has held various leadership roles including the Head of Global Quality, President and CEO of Teva API and President, and Group Executive Vice President and Chief Business Process Officer at Teva. Mr. Israeli obtained his MBA in Finance and Marketing from Bar Ilan University, Israel. Erez Israeli added, “I am excited to take the helm at Enzymotec, and I hope to continue building on the strong foundation that Ariel has laid by bringing a renewed vision to drive growth and success in the company’s range of businesses. I look forward to leveraging my deep experience in global markets to drive the expansion of the company’s growth opportunities to become a strong international player.” About Enzymotec Ltd. Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies. Forward Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions that convey uncertainty of future events or outcomes and the negatives of those terms. Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies, financing plans, competitive position, industry environment, potential growth opportunities, potential market opportunities and the effects of competition. Such statements involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Some of the important factors that could cause or contribute to such differences include the following: a high proportion of the sales of the INFAT® product is to our customers who then use it in their infant formula products sold to end users in China and therefore our revenues are subject to the effects of Chinese market trends and competition from locally produced products that are not subject to import taxes; growth in the Chinese economy has moderated and this slowdown and related volatility could adversely impact demand for our products in China; we are subject to a degree of customer concentration and our customers do not enter into long-term purchase commitments with us; the demand for products based on omega-3, and, in particular, premium products such as krill oil, has declined in the past and may continue to decline, which, together with a significant increase in capacity by competing manufacturers, may continue to cause intense competition and price pressures; Chinese regulations relating to infant formula are under re-examination, and any regulatory changes affecting the ability of our customers to market infant nutrition products containing INFAT® could adversely affect our business; we rely on our Swedish joint venture partner to manufacture INFAT®; a significant portion of the sales of our INFAT® product is to a single company and if this company were to suffer financially or reduce its use of INFAT® our business could be materially adversely affected; our results are subject to quarterly fluctuations; our offering of products as "medical foods" in the United States may be challenged by regulatory authorities and United States customs may then obstruct their import into the U.S.; our product development cycle is lengthy and uncertain, and our development or commercialization efforts for our products may be unsuccessful; our inventories include sensitive compounds which may face spoilage or obsolescence; we are dependent on a sole service provider for our direct to consumer medical food channel; potential future acquisitions of companies or technologies may require management’s time and attention, disrupt our business and not yield the returns expected; variations in the cost of raw materials for the production of INFAT® may have a material adverse effect on our business; we are dependent on a single facility that houses the majority of our operations; we anticipate that the markets in which we operate will become more competitive and we may be unable to compete effectively; we may have to pay royalties with respect to sales of our krill oil products in the United States or Australia and any infringement of intellectual property of others could also require us to pay royalties; unfavorable publicity or consumer perception of our products, the supplements that contain them as ingredients and any similar products distributed by other companies could have a material adverse effect on our reputation, the demand for our products and our business; we depend on third parties to obtain raw materials, in particular krill, necessary for the production of our products; we are generally reliant upon third parties for the distribution or commercialization of our products; we may not be able to maintain or increase market acceptance for our products; we are subject to risks relating to the operation and expansion of our production or processing facilities and capabilities; disruption to our IT system could adversely affect our reputation and have a material adverse impact on our business and results of operations; we are not able to predict the results of clinical trials, which may prove unsuccessful or be delayed by certain factors; our ability to obtain krill may be affected by conservation regulation or initiatives; we could be subject to product liability lawsuits, which could result in costly and time-consuming litigation and significant liabilities; and other factors discussed under the heading "Risk Factors" in our annual report on Form 20-F for the year ended December 31, 2015 filed with the Securities and Exchange Commission (the “SEC”) on March 3, 2016 and in other documents filed or furnished with the SEC. You should not put undue reliance on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.  

Contact

The Ruth Group
Tram Bui / Lee Roth
Phone: 646-536-7035 / 7012
[email protected]
[email protected]

Read more...
Julian Robertson Sells Half of Stake in John Paulson-Backed Company Hedge fund pioneer was fourth largest shareholder of 'medical foods' company
Roughly a year after starting to invest in the company, Julian Robertson (Trades, Portfolio) has chopped half his stake in Enzymotec Ltd. (NASDAQ:ENZY), a maker of nutritional ingredients and medical foods. Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.34
ENZY's PB Ratio is ranked higher than
83% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. ENZY: 1.34 )
Ranked among companies with meaningful PB Ratio only.
ENZY' s PB Ratio Range Over the Past 10 Years
Min: 0.91  Med: 1.47 Max: 11.01
Current: 1.34
0.91
11.01
PS Ratio 4.07
ENZY's PS Ratio is ranked higher than
73% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. ENZY: 4.07 )
Ranked among companies with meaningful PS Ratio only.
ENZY' s PS Ratio Range Over the Past 10 Years
Min: 1.41  Med: 3.64 Max: 5.84
Current: 4.07
1.41
5.84
EV-to-EBIT -33.82
ENZY's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. ENZY: -33.82 )
Ranked among companies with meaningful EV-to-EBIT only.
ENZY' s EV-to-EBIT Range Over the Past 10 Years
Min: -67.5  Med: 24.15 Max: 55.1
Current: -33.82
-67.5
55.1
EV-to-EBITDA -99.27
ENZY's EV-to-EBITDA is ranked lower than
100% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. ENZY: -99.27 )
Ranked among companies with meaningful EV-to-EBITDA only.
ENZY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -118.1  Med: 19.1 Max: 4653.8
Current: -99.27
-118.1
4653.8
Current Ratio 8.83
ENZY's Current Ratio is ranked higher than
75% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. ENZY: 8.83 )
Ranked among companies with meaningful Current Ratio only.
ENZY' s Current Ratio Range Over the Past 10 Years
Min: 2.31  Med: 7.59 Max: 9.06
Current: 8.83
2.31
9.06
Quick Ratio 5.97
ENZY's Quick Ratio is ranked higher than
65% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. ENZY: 5.97 )
Ranked among companies with meaningful Quick Ratio only.
ENZY' s Quick Ratio Range Over the Past 10 Years
Min: 1.5  Med: 5.52 Max: 7.31
Current: 5.97
1.5
7.31
Days Inventory 572.54
ENZY's Days Inventory is ranked lower than
94% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. ENZY: 572.54 )
Ranked among companies with meaningful Days Inventory only.
ENZY' s Days Inventory Range Over the Past 10 Years
Min: 121.07  Med: 251.79 Max: 572.54
Current: 572.54
121.07
572.54
Days Sales Outstanding 87.79
ENZY's Days Sales Outstanding is ranked lower than
59% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. ENZY: 87.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENZY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 76.82  Med: 108.17 Max: 120.92
Current: 87.79
76.82
120.92
Days Payable 102.80
ENZY's Days Payable is ranked higher than
67% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. ENZY: 102.80 )
Ranked among companies with meaningful Days Payable only.
ENZY' s Days Payable Range Over the Past 10 Years
Min: 102.78  Med: 106.61 Max: 145.45
Current: 102.8
102.78
145.45

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.00
ENZY's 3-Year Average Share Buyback Ratio is ranked higher than
85% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. ENZY: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ENZY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.8  Med: -2 Max: 0
Current: -2
-14.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 1.37
ENZY's Price-to-Tangible-Book is ranked higher than
87% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ENZY: 1.37 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ENZY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.1  Med: 1.46 Max: 6.82
Current: 1.37
1.1
6.82
Earnings Yield (Greenblatt) % -2.96
ENZY's Earnings Yield (Greenblatt) % is ranked higher than
64% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. ENZY: -2.96 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ENZY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.96  Med: 3.8 Max: 13.9
Current: -2.96
-2.96
13.9

More Statistics

Revenue (TTM) (Mil) $45.73
EPS (TTM) $ -0.19
Beta0.85
Short Percentage of Float0.79%
52-Week Range $5.20 - 9.32
Shares Outstanding (Mil)22.94

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) 0.50
EPS without NRI ($) 0.50
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ENZY

Headlines

Articles On GuruFocus.com
Enzymotec to Report First Quarter 2017 Financial Results May 03 2017 
VAYA Pharma Introduces New Three-Month Supply of Vayarin® and Vayacog® Medical Foods May 02 2017 
Neptune and Enzymotec Reach Patent Agreement Ending All Litigation Apr 03 2017 
Enzymotec Files Annual Report on Form 20-F for the Year Ended December 31, 2016 Mar 16 2017 
Enzymotec Ltd. Calls an Extraordinary General Meeting of Shareholders Mar 10 2017 
Enzymotec Ltd. Announces the Appointment of Erez Israeli as President and CEO Mar 09 2017 
Julian Robertson Adds to Multiple Positions in 3rd quarter Dec 20 2016 
Julian Robertson Cuts Half of Stake in Paulson-Backed Company Jul 01 2016 
Tiger Management Founder Julian Robertson Ups Stake in Enzymotec Dec 07 2015 
ENZYMOTEC 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General a Oct 31 2014 

More From Other Websites
Enzymotec misses 1Q profit forecasts May 17 2017
Enzymotec Ltd. Reports First Quarter 2017 Unaudited Financial Results May 17 2017
Investor Network: Enzymotec Ltd. to Host Earnings Call May 17 2017
Enzymotec to Report First Quarter 2017 Financial Results May 03 2017
VAYA Pharma Introduces New Three-Month Supply of Vayarin® and Vayacog® Medical Foods May 02 2017
Enzymotec Ltd. :ENZY-US: Earnings Analysis: Q4, 2016 By the Numbers : April 3, 2017 Apr 03 2017
Neptune and Enzymotec Reach Patent Agreement Ending All Litigation Apr 03 2017
Neptune and Enzymotec reach Patent Agreement Ending All Litigation Apr 03 2017
Enzymotec Files Annual Report on Form 20-F for the Year Ended December 31, 2016 Mar 16 2017
Enzymotec Ltd. Calls an Extraordinary General Meeting of Shareholders Mar 10 2017
Enzymotec Ltd. Announces the Appointment of Erez Israeli as President and CEO Mar 09 2017
Enzymotec reports 4Q loss Feb 22 2017
Does Enzymotec Ltd (ENZY) Stack Up To Its Peers In This Metric? Dec 15 2016
What Makes Enzymotec (ENZY) a Strong Sell? Dec 12 2016
Edited Transcript of ENZY earnings conference call or presentation 9-Aug-16 12:30pm GMT Aug 19 2016
Should You Get Rid of Enzymotec (ENZY) Now? Aug 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat